Eli Lilly and Company
corporate_fare Company Profile
Eli Lilly and Company (NYSE:LLY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 161 items for LLY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for LLY spans 10-Q, 8-K.
Recent high-impact activity:
- Mounjaro Wins Canadian Label Expansion for Cardiovascular Risk Reduction
- Lilly Signs Up-to-$5.9B Oncology Licensing Deal With Stipple Bio
- Lilly Pays $1.5B Cash for Private Biotech Calytrix Bio
- Lilly's Oral GLP-1 Wins China Approval, First Pill in a Market Seen at $4.5B
- China Approves Lilly's Oral Orforglipron; Hims Deal Adds Zepbound Access
Financial Snapshot
Short Interest & Short Volume
2.66 days to coverFINRA reported short interest of 7,213,927 shares in LLY as of the October 30, 2026 settlement, a 3.6% increase from the prior period — about 2.7 days to cover at its recent average daily volume. On November 20, 2026, 35.8% of LLY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.